MagicNurse

MagicNurse has developed the world’s first fully automated blood collection robot to receive NMPA Class III medical device certification, addressing the high-frequency, high-risk nature of manual venipuncture in clinical settings. The company’s robotic system enables unmanned, standardized blood specimen collection throughout the entire workflow.

Company Overview

Founded in November 2014 in Beijing, MagicNurse (迈纳士) emerged from founder Liu Zizhong’s vision to automate one of healthcare’s most routine yet risk-prone procedures. Liu, who holds a Master’s degree in Economics from Nankai University, previously spent 8 years working in China’s public health administration before launching Yantai Adcon Biotech in 2006, where he led development of China’s first fully automated ELISA analyzer.

The company is headquartered in the Beijing Economic-Technological Development Area (E-Town), operating from a modern R&D facility spanning approximately 1,000 square meters. The team of around 50 employees includes over 60% R&D personnel, led by researchers from the Chinese Academy of Sciences. MagicNurse maintains collaborative relationships with the Beihang University Robot Research Institute and Beijing Youan Hospital for clinical validation.

Core Products

MagicNurse Intelligent Venipuncture & Blood Collection Robot

The flagship product performs end-to-end automated venous blood collection, including automatic tube/needle supply, tourniquet application, spray disinfection, vein identification, needle insertion, blood drawing, and post-puncture dressing. Clinical studies at Zhongshan Hospital, Fudan University demonstrated a 94.3% puncture success rate, with specimen quality comparable to manual collection. Patient surveys indicated lower perceived pain compared to manual blood drawing.

MagicLab Blood Collection & Analysis System

Launched in 2023, this integrated system combines blood collection with on-site testing capabilities, targeting primary healthcare facilities. The device enables patients to receive standardized test reports within 10-15 minutes of sample collection.

Fully Automated Multi-function Analyzer

Received NMPA Class II certification in February 2025. Designed to work in conjunction with the blood collection robot, this analyzer expands the company’s coverage of the pre-analytical laboratory workflow.

Technology & Innovation

MagicNurse spent five years collecting over 200,000 vascular imaging samples to train its AI algorithms. The core technology stack includes:

• AI-powered machine vision for vein identification with over 97% recognition accuracy
• Image navigation control enabling precise needle positioning
• Automated puncture mechanics achieving first-stick success rates around 95%
• Intelligent interaction systems for patient communication during procedures

The company holds more than 30 patents covering biometric identification, image-guided control, and automated puncture technologies.

Market Presence

MagicNurse robots have been deployed at multiple major hospitals across China:

• Zhongshan Hospital, Fudan University (2021): Conducted comparative trials with 154 volunteers; 108 expressed willingness to use robotic blood collection again
• First Hospital of Anhui Medical University (2023): Installed 3 units at the Jixi Road campus; completed blood collection for over 5,100 patients by May 2024
• Nantong University Affiliated Hospital (2024): Deployed 2 units at the East Campus

Additional installations include Shandong Provincial Chest Hospital and Beijing Youan Hospital, with partnership discussions ongoing with PLA General Hospital (301), PLA 302 Hospital, Beijing Jishuitan Hospital, and Wuhan Tongji Hospital.

Key Milestones

• 2014: Company established in Beijing
• 2016: Prototype development completed; Angel round funding secured from Daokou Investment
• 2019: Obtained NMPA Class III medical device registration certificate
• 2020: Received ISO 13485 quality management system certification; commercial deployment began
• 2022: Launched second-generation blood collection robot; selected for CAST “Kechuang China” International Innovation Cooperation List
• 2023: Introduced MagicLab integrated collection-testing system
• 2024: Designated as Beijing “Specialized and Sophisticated” enterprise
• 2025: Multi-function analyzer received NMPA Class II certification

Frequently Asked Questions

What makes MagicNurse unique in the blood collection robot market?

MagicNurse developed the world’s first blood collection robot to obtain NMPA Class III certification, making it the only commercially approved autonomous venipuncture device globally as of 2025. The system covers the complete blood collection workflow from vein identification to post-puncture care.

Which patient populations can use the MagicNurse robot?

The current system is designed for patients aged 18 and above, with the latest generation expanding coverage to patients over 80 years old. Patients with tattoos, significant scarring, coagulation disorders, or arm/vascular abnormalities still require manual blood collection.

How does robotic blood collection compare to manual collection?

Clinical studies show the robot achieves a 94.3% puncture success rate with blood residue error of only 3% compared to 20% for manual collection. Patient surveys at Zhongshan Hospital found that 58% of participants reported lower pain levels with robotic collection, and 70% were willing to use it again.